Trial reportThe British journal of surgery2019
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.
Trial report in The British journal of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06166511 (Evaluation of Laparoscopic Non Anatomical Liver Resection in Hepatic Pathology), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Laparoscopic Non Anatomical Liver Resection in Hepatic Pathology
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Interplay of Tumor Morphology and Biology with Postoperative Complications: Prognostic Implications After Resection of Colorectal Liver Metastasis.Annals of surgical oncology · 2026Article
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization.Cardiovascular and interventional radiology · 2026Article
- Real-world outcomes of selective internal radiation therapy withFuture oncology (London, England) · 2025Observational
- Voxel-Based Dosimetry Predicts Local Tumor Progression Post 90 Y Radiation Segmentectomy of Colorectal Liver Metastases.Clinical nuclear medicine · 2025Article
- [Modern TARE 2023 - from palliative care to a curative treatment alternative].Nuklearmedizin. Nuclear medicine · 2024Article
- Article
- Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Interventional radiological therapies in colorectal hepatic metastases.Frontiers in oncology · 2023Review
- Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment.Cancers · 2022Review
- Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer.Cardiovascular and interventional radiology · 2022Review
- Postoperative complications predict poor outcomes only in patients with a low modified clinical score after resection of colorectal liver metastases: a retrospective cohort study.Updates in surgery · 2022Article
- Synergizing liver systemic treatments with interventional oncology: friend or foe?The British journal of radiology · 2022Review
- Pure laparoscopic major liver resection after yttriumLangenbeck's archives of surgery · 2022Article
- Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?The British journal of surgery · 2022Article
- Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A ReviewOncology (Williston Park, N.Y.) · 2022Article
- Tailored Systemic Therapy for Colorectal Cancer Liver Metastases.International journal of molecular sciences · 2021Review
- Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know.Seminars in interventional radiology · 2021Review
- Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases.Journal of gastrointestinal oncology · 2021Review
- Metastatic disease to the liver: Locoregional therapy strategies and outcomes.World journal of clinical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 19 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy.
methodsBaseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable.
resultsSome 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11·9 per cent) and control (25, 11·0 per cent) arms (P = 0·775). At follow-up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33·7 per cent) versus 54 of 472 (11·4 per cent) respectively (P = 0·001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38·1 per cent) versus 66 of 228 (28·9 per cent) respectively (P < 0·001).
conclusionAdding SIRT to chemotherapy may improve the resectability of unresectable CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.